 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...5051525354555657585960...858859» |
- |||||||||| divarasib (RG6330) / Roche, Lumakras (sotorasib) / Amgen
New P3 trial: Krascendo 1: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 11, 2024
P3, N=320, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||||||| GP40141 (romiplostim biosimilar) / Geropharm
New P3 trial: Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia (clinicaltrials.gov) - Jul 11, 2024
P3, N=160, Active, not recruiting, Sponsor: Geropharm
- | Lumakras (sotorasib) / Amgen
Journal: Sotorasib in KRAS-Mutated Colorectal Cancer. Reply. (Pubmed Central) - Jul 10, 2024
No abstract available
- | Lumakras (sotorasib) / Amgen
Journal: Sotorasib in KRAS-Mutated Colorectal Cancer. (Pubmed Central) - Jul 10, 2024
No abstract available No abstract available
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Retrospective data, Journal: Teprotumumab for Thyroid Eye Disease-related Strabismus. (Pubmed Central) - Jul 10, 2024
Extraocular motility in all 4 ductions also improved. A substantial minority of patients still required strabismus surgery following teprotumumab.
- || Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
Clinical, Review, Journal: An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review. (Pubmed Central) - Jul 10, 2024
The use of nivolumab is preferable as the second-line systemic therapy for unresectable HCC. More high-quality studies are urgently needed to generate quantitative analysis, and to encourage the formation of guidelines for second-line systemic therapy.
- | Prolia (denosumab) / Amgen
Journal: The Role of Denosumab Treatment in Recurrent Giant Cell Bone Tumor of the Orbit. (Pubmed Central) - Jul 10, 2024
Upon repeat excision, a diagnosis of GCTB was made. The patient started denosumab therapy and had no tumor growth over the ensuing 2 years, with stability of symptoms and clinical signs on follow-up.
- | Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis
Journal: Acute Renal Thrombotic Microangiopathy Caused by Eltrombopag and Romiplostim in a Patient with Myelodysplastic Syndromes (MDS) and Underlying Antiphospholipid Syndrome. (Pubmed Central) - Jul 10, 2024
The patient started denosumab therapy and had no tumor growth over the ensuing 2 years, with stability of symptoms and clinical signs on follow-up. Synthetic agonists of the thrombopoietin receptor, such as romiplostim or eltrombopag, can cause acute renal failure.Preexisting antiphospholipid (aPL) antibodies may increase the risk of renal failure.Screening for aPL antibodies should be considered before initiating thrombopoietin-receptor agonists (TPO-R agonists) in patients with immune thrombocytopenic purpura (ITP).
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Unmasking a Case of Sitosterolaemia: An Approach for Diagnosis and Management. (Pubmed Central) - Jul 10, 2024
Synthetic agonists of the thrombopoietin receptor, such as romiplostim or eltrombopag, can cause acute renal failure.Preexisting antiphospholipid (aPL) antibodies may increase the risk of renal failure.Screening for aPL antibodies should be considered before initiating thrombopoietin-receptor agonists (TPO-R agonists) in patients with immune thrombocytopenic purpura (ITP). Recognise the significance of considering sitosterolaemia in differential diagnosis for unexplained lipid abnormalities.Understand the challenges in diagnosing and managing sitosterolaemia, especially in patients with atypical responses to conventional lipid-lowering therapies.
- | Prolia (denosumab) / Amgen
Journal: A rare case of giant cell tumor of the anterior rib presenting as a breast mass. (Pubmed Central) - Jul 10, 2024
This case highlights the importance of keeping chest wall lesions in the differential for lesions presenting clinically as breast lesions. Despite the rarity of giant cell tumor of the anterior rib and its unusual presentation as a breast mass, appropriate diagnostic imaging work-up allowed for successful diagnosis and treatment in this case.
- || Review, Journal: Emerging therapies in the medical management of thyroid eye disease. (Pubmed Central) - Jul 10, 2024
Tocilizumab, a monoclonal antibody of interleukin 6, has played a role in the management of multiple autoimmune and inflammatory conditions and may offer promise in TED...Among the agents under investigation that aim to decrease ocular morbidity associated with TED are agents that IGF-1R, interleukin 6, and the neonatal Fc receptor. The management of TED continues to expand with novel immunologic approaches for disease therapy.
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: The association of race with thyroid eye disease presentation and outcomes. (Pubmed Central) - Jul 10, 2024
Black patients presented with fewer external exam findings suggestive of active TED compared to White patients, but the rate of compressive optic neuropathy and decompression surgery were similar in the two groups. These differences may be due to disease phenotypes, which warrant further study.
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Orbital corticosteroid injections for the treatment of active thyroid eye disease. (Pubmed Central) - Jul 10, 2024
To study the efficacy of orbital injections of triamcinolone acetonide mixed 1:1 with dexamethasone in the treatment of active thyroid eye disease...No steroid-responsive increases in intraocular pressure or injection-related complications were reported. Orbital steroid injections can successfully reduce symptoms of TED and may be a reliable tool in the treatment of TED as a relatively safe, fast-acting, efficacious treatment option, particularly as a bridge to other therapies.
- |||||| Ibrance (palbociclib) / Pfizer
New trial: A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer (clinicaltrials.gov) - Jul 10, 2024
P=N/A, N=5087, Active, not recruiting, Sponsor: Pfizer
- | maridebart cafraglutide (AMG 133) / Amgen
Journal: Antagonizing GIPR adds fire to the GLP-1R flame. (Pubmed Central) - Jul 9, 2024
Orbital steroid injections can successfully reduce symptoms of TED and may be a reliable tool in the treatment of TED as a relatively safe, fast-acting, efficacious treatment option, particularly as a bridge to other therapies. Unimolecular co-agonists at the GLP-1/GIP receptors have recently achieved remarkable anti-obesogenic feats; yet, in a recent Phase 1 clinical trial, V
- | Imdelltra (tarlatamab-dlle) / Amgen
Journal: Tarlatamab (Imdelltra) for small cell lung cancer. (Pubmed Central) - Jul 9, 2024
Unimolecular co-agonists at the GLP-1/GIP receptors have recently achieved remarkable anti-obesogenic feats; yet, in a recent Phase 1 clinical trial, V No abstract available
- | Journal: Comparison table: Some drugs for postmenopausal osteoporosis. (Pubmed Central) - Jul 9, 2024
No abstract available No abstract available
- || Review, Journal: Drugs for postmenopausal osteoporosis. (Pubmed Central) - Jul 9, 2024
No abstract available No abstract available
- | Stivarga (regorafenib) / Bayer
Journal: Stabilization of TGF-? Receptor 1 by a Receptor-Associated Adaptor Dictates Feedback Activation of the TGF-? Signaling Pathway to Maintain Liver Cancer Stemness and Drug Resistance. (Pubmed Central) - Jul 9, 2024
Collectively, targeting feedback machinery of TGF-? signaling pathway may be an actionable approach to mitigate drug resistance and liver cancer stemness.
- || Prolia (denosumab) / Amgen
Clinical, Retrospective data, Review, Journal, Metastases: Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis. (Pubmed Central) - Jul 9, 2024
Therefore, forming an overall judgement of the best ranked bone-modifying agent is challenging. More head-to-head comparisons, especially comparing denosumab with any bisphosphonate, are needed to address gaps and validate the findings of this review.
- | Enbrel (etanercept) / Pfizer, Amgen
Preclinical, Journal: Systemic low-dose anti-fibrotic treatment attenuates ovarian aging in the mouse. (Pubmed Central) - Jul 9, 2024
Transcriptomic analysis revealed that Pirfenidone treatment resulted in an upregulation of reproductive function-related genes at 8.5 months and a downregulation of inflammatory genes at 12 months of age. These findings demonstrate that reducing the fibroinflammatory ovarian microenvironment improves ovarian function, thereby supporting modulating the ovarian environment as a therapeutic avenue to extend reproductive longevity.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Journal: Transient Acquired Amegakaryocytic Thrombocytopenia in the Setting of Severe Sepsis: A Case Report. (Pubmed Central) - Jul 9, 2024
These findings demonstrate that reducing the fibroinflammatory ovarian microenvironment improves ovarian function, thereby supporting modulating the ovarian environment as a therapeutic avenue to extend reproductive longevity. Due to severe thrombocytopenia, filgrastim was administered.
- | Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, HEOR: The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics. (Pubmed Central) - Jul 9, 2024
For more than half the patients using fremanezumab or erenumab after 3-month period, MMD decreased by ?50% and total MIDAS score by >50 points. All areas of quality of life were improved after prophylactic treatment of migraine.
- || Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen
Review, Journal: Assessment of KRASG12C inhibitors for colorectal cancer. (Pubmed Central) - Jul 9, 2024
This review provides an update on clinical trials involving CRC patients treated with KRASG12C inhibitors as a monotherapy or combined with other drugs. Mechanisms that contribute to resistance to KRASG12C inhibitors and the development of novel RAS inhibitors with potential to escape such mechanisms of resistance are also discussed.
- | Blincyto (blinatumomab) / Astellas, Amgen
Retrospective data, Journal: The safety and efficacy of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia in children (Pubmed Central) - Jul 9, 2024
The median follow-up time for MC and IC group patients was 6.7 (5.2, 12.5) months and 7.1 (5.1, 7.6) months, respectively, with an event free survival rate of 100%. The safety and efficacy of using belintoumab in partial RR, MRD clearance, and chemotherapy intolerance are good.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Journal: High Creatinine Level Secondary to Use of CDK 4/6 Inhibitor Treatment (Palbociclib and Ribociclib) + Endocrine Therapy (ET). (Pubmed Central) - Jul 9, 2024
In conclusion, this study revealed that the increase in the serum creatinine secondary to ribociclib and palbociclib treatments is associated with kidney function tests and the number of concomitant diseases. Key Words: CDK 4/6 inhibitor, Creatinine elevation, Palbociclib, Ribociclib.
- | Imlygic (talimogene laherparepvec) / Amgen
Trial primary completion date, Metastases: Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer (clinicaltrials.gov) - Jul 9, 2024
P1, N=9, Active, not recruiting, Sponsor: Karie D. Runcie, MD
Key Words: CDK 4/6 inhibitor, Creatinine elevation, Palbociclib, Ribociclib. Trial primary completion date: Dec 2023 --> Dec 2024
- ||||||| MB09 (denosumab biosimilar) / Grupo Insud, Amneal, Korea Kolmar
Trial completion: A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia (clinicaltrials.gov) - Jul 8, 2024
P3, N=528, Completed, Sponsor: mAbxience Research S.L.
Trial primary completion date: Dec 2023 --> Dec 2024 Active, not recruiting --> Completed
- Repatha (evolocumab) / Amgen, Astellas
Cardiovascular Efficacy of Evolocumab in Patients with Obesity: Updates from FOURIER Trial (Bishkek) - Jul 8, 2024 - Abstract #ESC2024ESC_7420;
- Repatha (evolocumab) / Amgen, Astellas
Primary Results of SLICE-CEA CardioLink-8: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Characteristics in People with Asymptomatic High-Risk Carotid Stenosis (Bishkek) - Jul 8, 2024 - Abstract #ESC2024ESC_7380;
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Retrospective data, Journal, Metastases: Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group. (Pubmed Central) - Jul 8, 2024
Active, not recruiting --> Completed In RAS/BRAF wt mCRC patients, an anti-EGFR rechallenge provides a feasible therapeutic option with clinical benefit (survival) and a manageable safety profile.
- || Clinical, Retrospective data, Review: Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patients: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jul 8, 2024
In RAS/BRAF wt mCRC patients, an anti-EGFR rechallenge provides a feasible therapeutic option with clinical benefit (survival) and a manageable safety profile. This meta-analysis highlights the toxicity profiles of anti-angiogenic TKI monotherapies, and thus enables high-level recommendations for the choice of anti-angiogenic TKIs on the basis of the patient's age, ethnicity, comorbidities, and comedications, for personalized treatment.
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation. (Pubmed Central) - Jul 8, 2024
This meta-analysis highlights the toxicity profiles of anti-angiogenic TKI monotherapies, and thus enables high-level recommendations for the choice of anti-angiogenic TKIs on the basis of the patient's age, ethnicity, comorbidities, and comedications, for personalized treatment. No abstract available
- | Tavneos (avacopan) / Amgen
Journal: Avacopan's potential to decrease MPO-ANCA titres concurrent with ameliorated activity in ANCA-associated vasculitis. (Pubmed Central) - Jul 8, 2024
The present case implies that avacopan-mediated inhibition of C5a may lead to a reduction in MPO-ANCA levels, thereby potentially ameliorating the pathophysiology of ANCA-associated vasculitis. Nevertheless, the impact of avacopan on MPO-ANCA production cannot be asserted solely based on this report; therefore, further examination is necessary through subgroup analysis using data from larger-scale studies.
- | Prolia (denosumab) / Amgen
Journal: The comparative effect of teriparatide and denosumab on activins, follistatins and inhibins in women with postmenopausal osteoporosis. (Pubmed Central) - Jul 8, 2024
In conclusion, activins B and AB, as well as the ratios of all activins to follistatin and of activin AB to FSTL3 increased with teriparatide treatment, possibly in a compensatory manner. Future studies are needed to study the potentially important role activins may play in bone biology and any associations with the effect of teriparatide on BMD.
- | Parsabiv (etelcalcetide) / Amgen
Journal: Glutathione-Based Photoaffinity Probe Identifies Caffeine as a Positive Allosteric Modulator of the Calcium-Sensing Receptor. (Pubmed Central) - Jul 8, 2024
The effective concentration of caffeine for CaSR activation (<10 ?M) is easily attainable in plasma by ordinary caffeine consumption. Our report demonstrates the utility of a new chemical probe for CaSR and discovers a new protein target of caffeine, suggesting that caffeine consumption can modulate the diverse functions of CaSR.
- | Krazati (adagrasib) / BMS, Lumakras (sotorasib) / Amgen, RMC-7977 / Revolution Medicines
Journal: Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC. (Pubmed Central) - Jul 8, 2024
In patients with advanced KRASG12C-mutant NSCLC, the presence of mucinous histological features portended poor response to sotorasib or adagrasib. Our results have potential implications for personalized medicine and the development of rational RAS inhibitor-anchored therapeutic strategies.
- | Krazati (adagrasib) / BMS, MRTX1133 / BMS, Lumakras (sotorasib) / Amgen
Journal: Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. (Pubmed Central) - Jul 8, 2024
In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy...Combination treatment with KRASG12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies.
- || Review, Journal: Systemic Therapies for Hepatocellular Carcinoma in India. (Pubmed Central) - Jul 8, 2024
Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies. Systemic therapy for advanced HCC in India primarily involves the use of tyrosine kinase inhibitors
- | Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Journal: Lipid-lowering medications and risk of malignant melanoma: a Mendelian randomization study. (Pubmed Central) - Jul 8, 2024
No significant association was observed between NPC1L1 and melanoma. HMGCR inhibitors (statins) may increase melanoma risk, while PCSK9 inhibitors (evolocumab, alirocumab) could potentially decrease melanoma risk.
- | Qinlock (ripretinib) / Ono Pharma
Journal, Stroma: USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition. (Pubmed Central) - Jul 8, 2024
Moreover, ZDHHC18 can palmitoylate MDH2, preventing its ubiquitination and further increasing its protein stability. The research underscores the correlation between posttranslational modifications, specifically ubiquitination, and drug resistance, emphasizing the potential of targeting the USP5-MDH2 axis to counteract ripretinib resistance in GIST.
- || Tavneos (avacopan) / Amgen
Clinical, P1 data, Journal: A phase I thorough QT/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants. (Pubmed Central) - Jul 8, 2024
There was no clinically meaningful effect of avacopan on heart rate or cardiac conduction (PR and QRS intervals). Avacopan appeared to be generally well tolerated in this study population.
- Tepezza (teprotumumab-trbw) / Roche, Amgen
Efficacy of Teprotumumab on medical and surgical resistant DON (Aris Garoufalis Auditorium) - Jul 8, 2024 - Abstract #ETA2024ETA_485;
- Tepezza (teprotumumab-trbw) / Roche, Amgen
Response to Teprotumumab is Independent of Race, Ethnicity, and Age (Aris Garoufalis Auditorium) - Jul 8, 2024 - Abstract #ETA2024ETA_483;
- || AMG 193 / Amgen
Enrollment change: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Jul 8, 2024
P1, N=188, Recruiting, Sponsor: Amgen
Avacopan appeared to be generally well tolerated in this study population. N=282 --> 188
- || Vectibix (panitumumab) / Amgen
Trial primary completion date: OPTIPRIME: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (clinicaltrials.gov) - Jul 8, 2024
P2, N=118, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
N=282 --> 188 Trial primary completion date: Apr 2024 --> Dec 2024
- AMG 794 / Amgen
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov) - Jul 8, 2024
P1, N=3, Terminated, Sponsor: Amgen
N=98 --> 3 | Trial completion date: Feb 2028 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Dec 2023; Amgen has made the business decision to discontinue development of AMG 794. The safety profile of AMG 794 remains unchanged.
- | New P3 trial: The Sagittarius Trial (clinicaltrials.gov) - Jul 7, 2024
P3, N=700, Not yet recruiting, Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology
- | Lumakras (sotorasib) / Amgen
Journal, Circulating tumor DNA, Metastases: Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated non-small cell lung cancer treated with sotorasib. (Pubmed Central) - Jul 7, 2024
P=N/A
We identified KRAS amplifications as a potential recurring resistance mechanism to sotorasib. Identifying patients with superior prognosis could aid in optimizing time of treatment initiation, and identifying patients at risk of early progression could allow for earlier treatment decisions.
- Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Clinical Practice Expert Guidance for the use of Inebilizumab in NMOSD (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_1247;